Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
05 janv. 2023 09h15 HE
|
Cyclacel
– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tumors – – Expecting...
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
10 août 2022 16h05 HE
|
Cyclacel
- Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 – - Demonstrated evidence of target engagement for CDK2 and CDK9...